文献速递呼吸衰竭与机械通气心脑血管急症

西地那非联合吡非尼酮治疗晚期特发性肺纤维化伴肺动脉高压风险的2b期试验

Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
PubMed 文献 · Lancet Respir Med · 2020-08-18
一句话结论在晚期IPF且有第3组肺动脉高压风险的患者中,西地那非联合吡非尼酮较安慰剂联合吡非尼酮未改善52周疾病进展,无新安全信号。

这项多中心、国际、双盲、随机、安慰剂对照2b期研究在56个中心纳入177例晚期IPF(筛查时一氧化碳弥散量≤40%预计值)且有第3组肺动脉高压风险的患者,随机接受口服西地那非20 mg每日三次或安慰剂,均联合口服吡非尼酮801 mg每日三次,治疗52周。主要复合终点为疾病进展(6分钟步行距离相关下降、呼吸相关住院或全因死亡),西地那非组73%(64/88)vs 安慰剂组70%(62/89),组间差异3.06%(95%CI -11.30至17.97),p=0.65。严重治疗中出现不良事件西地那非组61%(54/88)vs 安慰剂组62%(55/89),导致死亡的治疗中出现不良事件分别为25%(22/88)vs 29%(26/89)。作者认为西地那非联合吡非尼酮未提供治疗获益,总体人群不适用,但需进一步研究特定亚组是否可能获益。

要点

  • 晚期IPF且有第3组肺动脉高压风险患者中,西地那非20 mg每日三次联合吡非尼酮801 mg每日三次治疗52周,疾病进展73% vs 70%,组间差异3.06%(95%CI -11.30至17.97),p=0.65。
  • 严重治疗中出现不良事件西地那非组61%(54/88)vs 安慰剂组62%(55/89),导致死亡的治疗中出现不良事件25%(22/88)vs 29%(26/89),无新安全信号。
  • 作者认为西地那非不是总体晚期IPF伴肺动脉高压风险人群的适当治疗,但需进一步研究特定亚组是否可能获益。
  • 纳入标准为年龄40-80岁、晚期IPF(一氧化碳弥散量≤40%预计值)且有第3组肺动脉高压风险(右心导管平均肺动脉压≥20 mmHg且肺动脉楔压≤15 mmHg,或超声中/高概率)。

适用人群与场景

  • 年龄40-80岁、晚期特发性肺纤维化(筛查时一氧化碳弥散量≤40%预计值)且有第3组肺动脉高压风险的患者。
  • 第3组肺动脉高压风险定义:既往右心导管平均肺动脉压≥20 mmHg且肺动脉楔压≤15 mmHg,或超声心动图中/高概率第3组肺动脉高压(按2015年欧洲心脏病学会和欧洲呼吸学会指南)。
  • 研究在加拿大、欧洲(比利时、捷克、德国、希腊、匈牙利、意大利、荷兰、西班牙、土耳其)、以色列和非洲(埃及、南非)的56个大学诊所、研究医院和三级中心进行。

诊断标准与关键阈值

  • 晚期IPF:筛查时一氧化碳弥散量≤40%预计值。
  • 第3组肺动脉高压风险:既往右心导管平均肺动脉压≥20 mmHg且肺动脉楔压≤15 mmHg,或超声心动图中/高概率第3组肺动脉高压(2015年欧洲心脏病学会和欧洲呼吸学会指南定义)。

处置流程与药物剂量

  • 西地那非组:口服西地那非片20 mg每日三次,联合口服吡非尼酮胶囊801 mg每日三次,疗程52周。
  • 安慰剂组:口服安慰剂,联合口服吡非尼酮胶囊801 mg每日三次,疗程52周。
  • 随机化按既往右心导管(是/否)和第一秒用力呼气容积/用力肺活量比值(<0.8或≥0.8)分层,1:1分配。

研究设计与关键结果

  • 多中心、国际、双盲、随机、安慰剂对照2b期研究,在56个中心纳入177例患者(西地那非组88例,安慰剂组89例),均纳入主要终点分析。
  • 主要复合终点(52周疾病进展:6分钟步行距离相关下降、呼吸相关住院或全因死亡):西地那非组64/88(73%)vs 安慰剂组62/89(70%),组间差异3.06%(95%CI -11.30至17.97),p=0.65。
  • 严重治疗中出现不良事件:西地那非组54/88(61%)vs 安慰剂组55/89(62%)。
  • 导致死亡的治疗中出现不良事件:西地那非组22/88(25%)vs 安慰剂组26/89(29%)。

证据类型、等级与局限

  • 证据类型:多中心、国际、双盲、随机、安慰剂对照2b期试验。
  • 作者结论:西地那非联合吡非尼酮在晚期IPF伴肺动脉高压风险患者中至52周未提供治疗获益,无新安全信号;虽然缺乏有益治疗效应提示西地那非不是总体人群的适当治疗,但需进一步研究特定亚组是否可能获益。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于晚期IPF(一氧化碳弥散量≤40%预计值)且有第3组肺动脉高压风险的患者,加用西地那非20 mg每日三次至吡非尼酮801 mg每日三次未改善52周疾病进展。
  • 作者认为西地那非不是总体晚期IPF伴肺动脉高压风险人群的适当治疗,但需进一步研究特定亚组是否可能获益。
  • 原文未据此给出推荐。

指南或共识出处

  • Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial(Lancet Respir Med),临床试验注册号NCT02951429。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis (IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or likely to develop, is uncertain. We aimed to assess the efficacy and safety of sildenafil added to pirfenidone versus placebo added to pirfenidone for 52 weeks in patients with advanced IPF and at risk of group 3 pulmonary hypertension.

METHODS: We did a multicentre, international, double-blind, randomised, placebo-controlled, phase 2b study at 56 university clinics, research hospitals, and tertiary sites in Canada, Europe (Belgium, Czech Republic, Germany, Greece, Hungary, Italy, the Netherlands, Spain, and Turkey), Israel, and Africa (Egypt and South Africa). Eligible patients (aged 40-80 years) had advanced IPF (carbon monoxide diffusing capacity ≤40% predicted at screening), and were at risk of group 3 pulmonary hypertension (mean pulmonary artery pressure of ≥20 mm Hg with pulmonary artery wedge pressure of ≤15 mm Hg on previous right-heart catheterisation, or intermediate or high probability of group 3 pulmonary hypertension on echocardiography as defined by the 2015 European Society of Cardiology and European Respiratory Society guidelines). Patients were randomly assigned 1:1 to oral sildenafil tablets (20 mg three times daily) or placebo, both in addition to oral pirfenidone capsules (801 mg three times daily), using a validated interactive voice-based or web-based response system with permuted block randomisation, stratified by previous right-heart catheterisation (yes or no) and forced expiratory volume in 1 s to forced vital capacity ratio (<0·8 or ≥0·8). The composite primary endpoint was disease progression, defined as either a relevant decline in 6-min walk distance, respiratory-related admission to hospital, or all-cause mortality, after 52 weeks and was assessed in the intention-to-treat population; safety was assessed in all patients who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, NCT02951429, and is no longer recruiting. The 11-month safety follow-up is ongoing.

FINDINGS: Between Jan 13, 2017, and Aug 30, 2018, 247 patients were screened for eligibility, 177 of whom were randomly assigned to a treatment group (n=88 sildenafil; n=89 placebo) and were assessed for the primary outcome. There was no difference in the proportion of patients with disease progression over 52 weeks between the sildenafil (64 [73%] of 88 patients) and placebo groups (62 [70%] of 89 patients; between-group difference 3·06% [95% CI -11·30 to 17·97]; p=0·65). Serious treatment-emergent adverse events were reported in 54 (61%) patients in the sildenafil group and 55 (62%) patients in the placebo group. Treatment-emergent adverse events leading to mortality occurred in 22 (25%) patients in the sildenafil group and 26 (29%) in the placebo group.

INTERPRETATION: Addition of sildenafil to pirfenidone did not provide a treatment benefit versus pirfenidone plus placebo up to 52 weeks in patients with advanced IPF and risk of pulmonary hypertension. No new safety signals were identified with either treatment. Although the absence of a beneficial treatment effect suggests that sildenafil is not an appropriate treatment in the overall population, further research is required to establish if specific subgroups of patients with IPF might benefit from sildenafil.

FUNDING: F Hoffmann-La Roche.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Behr J, Nathan SD, Wuyts WA, et al. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2020. PMID: 32822614. doi:10.1016/S2213-2600(20)30356-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。